You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Managing Resistant/Refractory Cytomegalovirus Infection in Transplant Patients: Understanding the Drugs and the Data

  • Authors: Camille Nelson Kotton, MD, FIDSA, FAST; Emily A. Blumberg, MD; Genovefa Papanicolaou, MD
  • CME / ABIM MOC Released: 3/2/2022
  • Valid for credit through: 3/2/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, infectious disease (ID)/HIV specialists, and transplant surgeons.

The goal of this activity is to educate clinicians on the clinical data and mechanisms of action (MoAs) of emerging therapies for the management of resistant/refractory (R/R) cytomegalovirus (CMV) infection to improve patient care.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data for emerging therapies for the management of R/R CMV infection
    • MoAs of emerging therapies for the management of R/R CMV infection


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Moderator

  • Camille Nelson Kotton, MD, FIDSA, FAST

    Clinical Director
    Transplant and Immunocompromised Host Infectious Diseases
    Infectious Diseases Division
    Massachusetts General Hospital
    Harvard Medical School
    Boston, Massachusetts 

    Disclosures

    Disclosure: Camille Nelson Kotton, MD, FISA, FAST, has the following relevant financial relationships: 
    Advisor or consultant for: BeiGene (Beijing) Co., Ltd; Evrys; Hookipa; Merck; resTORbio; Synklino; Takeda
    Speaker or a member of a speakers bureau for: Roche Diagnostics; Takeda
    Grants for clinical research from: AiCuris; BeiGene (Beijing) Co., Ltd.; BioHOPE

Faculty

  • Emily A. Blumberg, MD

    Professor of Medicine
    Hospital of the University of Pennsylvania 
    Program Director
    Infectious Disease Fellowship
    Philadelphia, Pennsylvania

    Disclosures

    Disclosure: Emily A. Blumberg, MD, has the following relevant financial relationships: 
    Advisor or consultant for: Merck
    Grants for clinical research from: Merck; Hologics, Inc.; Takeda
    Other: Member of data and safety monitoring board (DSMB) for Amplyx

  • Genovefa Papanicolaou, MD

    Director, Clinical Trials
    Infectious Disease Service
    Memorial Sloan Kettering Cancer Center
    Weill Cornell Medicine
    New York, New York

    Disclosures

    Disclosure: Genovefa Papanicolaou, MD, has the following relevant financial relationships: 
    Advisor or consultant for: Amplyx; AlloVir; Astellas Pharma, Inc (ended September 2021).; Cidara Therapeutics; CSL Behring; Partners Rx (ended January 2021); Shionogi & Co., Ltd (ended October 2021).; SymBio Pharmaceuticals Limited; Takeda; Vera Therapeutics
    Speaker or a member of a speakers bureau for: Merck
    Grants for clinical research from: Merck

Editors

  • Iwona Misiuta, PhD, MHA

    Medical Education Director, Medscape, LLC 

    Disclosures

    Disclosure: Iwona Misiuta, PhD, MHA, has disclosed no relevant financial relationships.  

  • Renata Feldman, PharmD

    Scientific Content Manager, Medscape, LLC 

    Disclosures

    Disclosure: Renata Feldman, PharmD, has disclosed no relevant financial relationships.  

Compliance Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Managing Resistant/Refractory Cytomegalovirus Infection in Transplant Patients: Understanding the Drugs and the Data

Authors: Camille Nelson Kotton, MD, FIDSA, FAST; Emily A. Blumberg, MD; Genovefa Papanicolaou, MDFaculty and Disclosures

CME / ABIM MOC Released: 3/2/2022

Valid for credit through: 3/2/2023

processing....

Assessment Survey

Before you begin, please take this brief survey.